Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arsenic--Toxicology
Conditions
Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired, Micronutrient Deficiency, Influenza
Trial Timeline
Oct 14, 2018 → Jan 6, 2020
NCT ID
NCT03930017About Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)
Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated) is a pre-clinical stage product being developed by Sanofi for Arsenic--Toxicology. The current trial status is completed. This product is registered under clinical trial identifier NCT03930017. Target conditions include Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03930017 | Pre-clinical | Completed |